# Glaucoma guideline committee meeting 6

**Date:** 28/02/2017

Location: Boardroom, National Guideline Centre, 180 Great Portland Street,

London W1W 5QZ

Minutes: Confirmed

NICE National Institute for Health and Care Excellence

Committee members present:	
John Sparrow (JS, Chair)	(Present for notes 1–5)
Augusto Azuara Blanco (AAB)	(Present for notes 1–5)
Jane Bell (JB)	(Present for notes 1–5)
Clare Faulkner (CF)	(Present for notes 1–5)
Cecilia Fenerty (CFen)	(Present for notes 1–5)
Paul Foster (PF)	(Present for notes 1–5)
Robert Harper (RH)	(Present for notes 1–5)
David Parkins (DP)	(Present for notes 1–5)
Rebecca Turner (RT)	(Present for notes 1–5)

In attendance:		
Ben Doak (BD)	Guideline Commissioning Manager, NICE	(Present for notes 1–5b)
Anne-Louise Clayton (ALC)	Editor, NICE	(Present for notes 1–5b)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–5)
Jessica Glen (JG)	Senior Research Fellow, NGC	(Present for notes 1–5)
Jennifer Hill (JH)	Operations Director/Guideline Lead, NGC	(Present for notes 1–5)
Emma Pottinger (EP)	Research Fellow, NGC	(Present for notes 1–5)
Lauren Ramjee (LR)	Health Economist, NGC	(Present for notes 1–5)
Hannah Trippier (HT)	Senior Research Fellow, NGC	(Present for notes 1–5)

Apologies:	
Anomika Bedi (AB)	Lay member
Kamal Bishai (KB)	General practitioner, special interest Ophthalmology
Helen Doe (HD)	Lay member

Jill Cobb (JC)	Information Specialist, NGC
Ben Pordes (BP)	Acting Senior Project Manager, NGC

## 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the sixth meeting on Glaucoma: diagnosis and management. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included the results of the health economics model, treatment recommendations and the Accuracy II (structural tests for glaucoma damage) evidence reviews.

#### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were the results of the health economics model, treatment recommendations and the Accuracy II evidence reviews.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

There were no new declarations.

The Chair and a senior member of the Developer's team noted that the following members would not participate in a part of the meeting:

- Augusto Azuara Blanco disclosed that he was the lead author on one of the studies discussed during today's meeting.
- Robert Harper observed the discussions related to the health economics model and treatments due to a previous declaration regarding pharmacological treatments.
- David Parkins disclosed that he was the lead author on one of the studies discussed during today's meeting.

### 3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

#### 4. Presentations and discussion

- a. LR presented the results of the Health Economic Model. The committee discussed the results of the model and drafted recommendations based on its results.
- b. EP presented the evidence for the review question of 'What is the accuracy of structural tests for identifying and monitoring progression of glaucoma damage (that is, optic nerve head/optic disk damage, macular and retinal nerve fibre layer damage)?' The committee discussed the recommendations for the treatment of glaucoma. The committee then drafted recommendations.
- c. LR presented the health economic evidence for the service delivery review. The committee discussed the presentation.
- d. The committee drafted recommendations for diagnostics and monitoring intervals.

_	•	4			
_	A 101/	A+hAr	hiic	iness	
-	<b>4</b> 110	()			
•	$\sim$	Othion	NUU	,,,,,,,,,,	

None.

**Date of next meeting:** GC7 - 01/03/2017

**Location of next meeting:** Boardroom, NGC, 180 Great Portland Street, London

W1W 5QZ